NasdaqGM:CRMDPharmaceuticals
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention
CorMedix (NasdaqGM:CRMD) has agreed to acquire Melinta Therapeutics, adding seven approved therapies to its commercial portfolio.
The transaction expands CorMedix's presence in hospital and acute care settings through a broader anti infective offering.
The deal marks a shift from a single product focused model toward a multi asset commercial platform.
For you as an investor, CorMedix has largely been known for its focus on infection prevention products in high risk settings. By bringing...